<DOC>
	<DOCNO>NCT00795925</DOCNO>
	<brief_summary>The open-label dose-escalating two-centre study design ass pharmacokinetics well safety , tolerability efficacy parameter propiverine patient 5-10 year age suffer frequency-urgency-syndrome urinary incontinence indicative detrusor overactivity ( overactive bladder ) determination recommend dose child .</brief_summary>
	<brief_title>Dose-Escalating Study Propiverine Hydrochloride Children Suffering From Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Propiverine</mesh_term>
	<criteria>Main Micturition Frequency ≥6 micturition awake period Urge Incontinence Episodes ≥1/week Urgency Episodes ≥1/day Main Contraindication anticholinergic therapy Repeated measurement Post Void Residual ≥20 mL Nocturnal Enuresis Clinically significant cardiovascular , hepatic , renal , gastrointestinal hematological disease , psychiatric disorder diabetes insipidus Anatomical abnormality urinary tract</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>propiverine</keyword>
	<keyword>anticholinergic</keyword>
	<keyword>urinary incontinence</keyword>
	<keyword>overactive bladder</keyword>
	<keyword>child</keyword>
	<keyword>dose-finding child age 5-10 year</keyword>
</DOC>